CD274 and non-small cell lung carcinoma: This was bolstered by the phase II CITYSCAPE (NCT03563716) in chemotherapy-naïve, PD-L1-positive NSCLC, where a combination of tiragolumab plus atezolizumab significantly improved ORR (31.3% vs. 16.2%, p = 0.031) compared to atezolizumab with a comparable safety profile (G3/4 TRAEs: 21% vs. 18%), suggesting good tolerability for the dual blockade [58].